[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Danish Headache Center\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":282},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,11,0,[8,51,77,110,129,151,175,196,218,240,261],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":35,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":40,"startDateStruct":43,"completionDateStruct":45,"leadSponsor":47,"locationsCount":50},"100627679","selective-activation-of-the-adrenomedullin-receptors-in-migraine-100627679",false,"NCT07451769","Selective Activation of the Adrenomedullin Receptors in Migraine","Selective Activation of the Adrenomedullin Receptors in Migraine: A Randomized, Double-Blind, Placebo-Controlled Crossover Study","Inclusion Criteria:\n\n1. Written informed consent has been obtained prior to the initiation of any study-specific procedures.\n2. Age ≥18 years at the time of screening.\n3. History of migraine without aura for at least 12 months prior to screening, with a frequency of 1-5 migraine attacks per month, based on medical records and\u002For patient self-report, and diagnosed in accordance with the ICHD-3 criteria.\n\nExclusion Criteria:\n\n1. History of any other primary headache disorder, except for tension-type headache with \\\u003C5 headache days per month, based on ICHD-3 classification.\n2. History of any secondary headache disorder, per ICHD-3 criteria, prior to screening.\n3. Use of prophylactic migraine medication within 30 days or within 5 plasma half-lives (whichever is longer) prior to screening.\n4. Previous use of any therapies targeting the CGRP signaling pathway, including anti-CGRP ligand monoclonal antibodies, anti-CGRP receptor monoclonal antibodies, or small molecule CGRP receptor antagonists.\n5. Known risk of self-harm or harm to others, including a history of suicidal behavior.\n6. Any clinically significant disorder, condition, or disease (other than those permitted in the protocol) that, in the opinion of the investigator, could compromise participant safety or interfere with study procedures or data integrity.\n7. Positive urine pregnancy test at screening or on Day 1 in female participants of childbearing potential.\n8. Pregnancy or breastfeeding, or plans to become pregnant or breastfeed during the study period.\n9. Evidence of current pregnancy or breastfeeding based on self-report or medical records.\n10. Inability or unwillingness to complete all protocol-required visits and procedures, or concerns regarding protocol adherence, as judged by the investigator.","ALL","18 Years","65 Years",{"count":20,"type":21},26,"ESTIMATED","INTERVENTIONAL",[24],"NA","Adrenomedullin is a neuropeptide implicated in the pathogenesis of migraine. This study investigates whether its administration, after pre-treatment with erenumab (a CGRP-receptor blocking monoclonal antibody), can trigger migraine attacks in individuals with migraine without aura.",[27,28,29,30,31,32,33,34],"Migraine","Brain Diseases","Central Nervous System Diseases","Adrenomedullin","Pain","Peptides","Neuropeptides","Signs and Symptoms",[36,37,31],"Migraine Disorders","Adrenomedulin","NOT_YET_RECRUITING","2026-03-05",{"date":41,"type":42},"2026-03-09","ACTUAL",{"date":44,"type":21},"2026-03-10",{"date":46,"type":21},"2032-12-20",{"name":48,"class":49},"Danish Headache Center","OTHER",1,{"id":52,"slug":53,"hasResults":11,"nctId":54,"briefTitle":55,"officialTitle":56,"acronym":4,"eligibilityCriteria":57,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":58,"targetDuration":4,"studyType":22,"phases":60,"briefSummary":61,"conditions":62,"keywords":65,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":4},"100619259","induction-of-migraine-attacks-with-aura-using-pituitary-adenylate-cyclase-activating-polypeptide-38-100619259","NCT07342296","Induction of Migraine Attacks With Aura Using Pituitary Adenylate Cyclase Activating Polypeptide-38","Induction of Migraine Attacks With Aura Using Pituitary Adenylate Cyclase Activating Polypeptide-38: A Randomized Clinical Trial","Inclusion Criteria:\n\n* Age 18 to 65 years of age upon entry into screening\n* History of migraine with aura for ≥ 12 months according to the International Classification of Headache Disorders 3rd Edition (ICHD-3) criteria\n* ≥ 1 monthly day with aura that meets criteria as aura on average across the three months before screening\n* Provision of informed consent prior to initiation of any study-specific activities\u002Fprocedures.\n\nExclusion Criteria:\n\n* Any history of a primary or secondary headache disorder other than migraine without aura, migraine with aura, chronic migraine, and episodic tension-type headache\n* History or evidence of any other clinically significant disorder, condition, or disease (except for those outlined above) that, in the opinion of the site investigator, would pose a risk to subject safety or interfere with study evaluation, procedures or completion\n* The subject is at risk of self-harm or harm to others as evidenced by past suicidal behavior\n* Female subjects of childbearing potential with a positive pregnancy test during any study visit\n* Cardiovascular disease of any kind, including cerebrovascular diseases Hypertension (systolic blood pressure of ≥150 mmHg and\u002For diastolic blood pressure of ≥100 mmHg) prior to the start of infusion on the experimental day Hypotension (systolic blood pressure of ≤90 mmHg and\u002For diastolic blood pressure of ≤50 mmHg)\n* Initiation, discontinuation, or change of dosing of prophylactic medications within 2 months prior to study inclusion\n* Intake of acute medications (e.g. analgesics, triptans) within 48 hours of infusion start\n* Headache of any intensity within 48 hours of infusion start\n* Aura within 48 hours of infusion start",{"count":59,"type":21},21,[24],"Pituitary Adenylate Cyclase Activating Polypeptide-38 (PACAP-38) is a key neuropeptide in migraine pathophysiology and treatment. This study investigates whether PACAP-38 administration can trigger aura in individuals with a diagnosis of migraine with aura.",[63,64],"Migraine With Aura","Migraine Aura",[66,67,68],"migraine","aura","Pituitary Adenylate Cyclase Activating Polypeptide-38","2026-01-08",{"date":71,"type":42},"2026-01-15",{"date":73,"type":21},"2026-02-01",{"date":75,"type":21},"2026-12-30",{"name":48,"class":49},{"id":78,"slug":79,"hasResults":11,"nctId":80,"briefTitle":81,"officialTitle":82,"acronym":4,"eligibilityCriteria":83,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":84,"targetDuration":4,"studyType":22,"phases":85,"briefSummary":86,"conditions":87,"keywords":100,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":102,"lastUpdatePostDateStruct":103,"startDateStruct":105,"completionDateStruct":107,"leadSponsor":109,"locationsCount":50},"100619142","hypersensitivity-to-amylin-in-post-traumatic-headache-100619142","NCT07340775","Hypersensitivity to Amylin in Post-Traumatic Headache","Hypersensitivity to Amylin in Post-Traumatic Headache: A Randomized Clinical Trial","Inclusion Criteria:\n\n* Age 18 to 65 years of age upon entry into screening\n* History of persistent headache attributed to mild traumatic injury to the head for ≥ 12 months and in accordance with the International Classification of Headache Disorders, 3rd Edition (ICHD-3)\n* ≥ 4 monthly headache days on average across the 3 months prior to screening\n* Provision of informed consent prior to initiation of any study-specific activities\u002Fprocedures\n\nExclusion Criteria:\n\n* \\> 1 mild traumatic injury to the head\n* History of any primary or secondary headache disorder prior to mild traumatic injury to the head (except for infrequent episodic tension-type headache)\n* History of moderate or severe injury to the head\n* History of whiplash injury\n* History of craniotomy\n* History or evidence of any other clinically significant disorder, condition or disease (except for those outlined above) than, in the opinion of the site investigator, would pose a risk to subject safety or interfere with study evaluation, procedures or completion\n* The subject is at risk of self-harm or harm to others as evidenced by past suicidal behavior\n* Female subjects of childbearing potential with a positive pregnancy test during any study visit\n* Cardiovascular disease of any kind, including cerebrovascular diseases\n* Hypertension (systolic blood pressure of ≥150 mmHg and\u002For diastolic blood pressure of ≥100 mmHg) prior to the start of infusion on the experimental day\n* Hypotension (systolic blood pressure of ≤90 mmHg and\u002For diastolic blood pressure of ≤50 mmHg)\n* Initiation, discontinuation, or change of dosing of prophylactic medications within 2 months prior to study inclusion\n* Intake of acute medications (e.g. analgesics, triptans) within 48 hours of infusion start\n* Baseline headache intensity of \\>3 on an 11-point numeric rating scale (0 being no headache, 10 being the worst imaginable headache)\n* Baseline migraine-like headache or self-reported baseline headache that mimics the subjects' usual migraine-like headache",{"count":59,"type":21},[24],"Pramlintide is a peptide analogue of human amylin which is a vasoactive substance involved in the pathogenesis of headache. This study investigates whether pramlintide induces migraine-like headache in people with persistent post-traumatic headache (PTH) attributed to mild traumatic brain injury (mTBI).",[88,28,89,90,29,91,34,92,93,31,94,95,96,32,97,98,99],"Headache Disorders, Secondary","Headache Disorders","Nervous System Diseases","Neurologic Manifestations","Pathological Conditions, Signs and Symptoms","Post-Traumatic Headache","Peptide Hormones","Hormones","Hormones, Hormone Substitutes, and Hormone Antagonists","Amino Acids, Peptides, and Proteins","Amylin","Pramlintide",[101,31,98],"Post-traumatic headache","2026-01-05",{"date":104,"type":42},"2026-01-14",{"date":106,"type":21},"2026-02",{"date":108,"type":21},"2028-12",{"name":48,"class":49},{"id":111,"slug":112,"hasResults":11,"nctId":113,"briefTitle":114,"officialTitle":115,"acronym":4,"eligibilityCriteria":116,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":117,"targetDuration":4,"studyType":22,"phases":118,"briefSummary":119,"conditions":120,"keywords":123,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":102,"lastUpdatePostDateStruct":124,"startDateStruct":125,"completionDateStruct":126,"leadSponsor":128,"locationsCount":50},"100619143","amylin-induced-migraine-attacks-without-aura-100619143","NCT07340788","Amylin-Induced Migraine Attacks Without Aura","Amylin-Induced Migraine Attacks Without Aura: A Randomized Clinical Trial","Inclusion Criteria:\n\n* Age 18 to 65 years of age upon entry into screening\n* A body weight of 50 to 100 kg\n* History of migraine without aura for ≥12 months and in accordance with ICHD-3\n* Between 1-5 monthly migraine days without aura on average across the 3 months prior to screening\n* Provision of informed consent prior to initiation of any study-specific activities\u002Fprocedures\n\nExclusion Criteria:\n\n* Any history of a primary or secondary headache disorder other than migraine without aura and infrequent episodic tension-type headache\n* Any history of moderate to severe traumatic brain injury\n* Any history of cardiovascular disease, including cerebrovascular diseases\n* Any history of pulmonary disease\n* Any other clinically significant disorders, conditions, or diseases that might impact the safety of the subject or interfere with the study's evaluation, procedures, or completion, aside from those mentioned above. This includes any relevant medical history or evidence that, in the opinion of the site investigator, might pose a risk to the subject or impact the validity of the study results\n* The subject is at risk of self-harm or harm to others as evidenced by past suicidal behavior\n* Female subjects of childbearing potential with a positive pregnancy test during any study visit\n* Cardiovascular disease of any kind, including cerebrovascular diseases\n* Hypertension (systolic blood pressure of ≥150 mmHg and\u002For diastolic blood pressure of ≥100 mmHg) prior to the start of infusion on the experimental day\n* Hypotension (systolic blood pressure of ≤90 mmHg and\u002For diastolic blood pressure of ≤50 mmHg)\n* Abnormalities on the electrocardiogram that, in the opinion of the site investigator, might pose a risk to the subject or impact the validity of the study results\n* Daily use of any medication other than contraceptives\n* Intake of any medication other than contraceptives within 48 hours of infusion start\n* Intake of caffeine, nicotine, and alcohol within 12 hours of infusion start\n* Headache of any intensity within 48 hours of infusion start\n* Migraine attack within 48 hours of infusion start\n* Aura within 48 hours of infusion start",{"count":59,"type":21},[24],"Pramlintide is a peptide analogue of human amylin which is a vasoactive signaling molecule involved in the pathogenesis of migraine. This study investigates whether pramlintide induces migraine attacks without aura in people with migraine without aura.",[121,89,28,90,29,91,34,92,36,122,31,94,95,96,32,97,98,99],"Headache Disorders, Primary","Headache",[27,122,31,98],{"date":104,"type":42},{"date":106,"type":21},{"date":127,"type":21},"2028-10-30",{"name":48,"class":49},{"id":130,"slug":131,"hasResults":11,"nctId":132,"briefTitle":133,"officialTitle":134,"acronym":4,"eligibilityCriteria":135,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":136,"targetDuration":4,"studyType":22,"phases":137,"briefSummary":138,"conditions":139,"keywords":140,"overallStatus":143,"whyStopped":4,"lastUpdateSubmitDate":144,"lastUpdatePostDateStruct":145,"startDateStruct":147,"completionDateStruct":149,"leadSponsor":150,"locationsCount":50},"100594623","induction-of-migraine-attacks-with-aura-using-calcitonin-gene-related-peptide-100594623","NCT07021859","Induction of Migraine Attacks With Aura Using Calcitonin Gene-Related Peptide","Induction of Migraine Attacks With Aura Using Calcitonin Gene-Related Peptide: A Randomized Clinical Trial","Inclusion Criteria:\n\n* Age 18 to 65 years of age upon entry into screening\n* History of migraine with aura for ≥ 12 months according to the International Classification of Headache Disorders 3rd Edition (ICHD-3) criteria\n* ≥ 1 monthly day with aura that meets criteria as aura on average across the three months before screening\n* Provision of informed consent prior to initiation of any study-specific activities\u002Fprocedures.\n\nExclusion Criteria:\n\n* Any history of a primary or secondary headache disorder other than migraine without aura, migraine with aura, chronic migraine, and episodic tension-type headache\n* History or evidence of any other clinically significant disorder, condition, or disease (except for those outlined above) that, in the opinion of the site investigator, would pose a risk to subject safety or interfere with study evaluation, procedures or completion\n* The subject is at risk of self-harm or harm to others as evidenced by past suicidal behavior\n* Female subjects of childbearing potential with a positive pregnancy test during any study visit\n* Cardiovascular disease of any kind, including cerebrovascular diseases\n* Hypertension (systolic blood pressure of ≥150 mmHg and\u002For diastolic blood pressure of ≥100 mmHg) prior to the start of infusion on the experimental day\n* Hypotension (systolic blood pressure of ≤90 mmHg and\u002For diastolic blood pressure of ≤50 mmHg)\n* Initiation, discontinuation, or change of dosing of prophylactic medications within 2 months prior to study inclusion\n* Intake of acute medications (e.g. analgesics, triptans) within 48 hours of infusion start\n* Headache of any intensity within 48 hours of infusion start\n* Aura within 48 hours of infusion start",{"count":59,"type":21},[24],"Calcitonin gene-related peptide (CGRP) is a key neuropeptide in migraine pathophysiology and treatment. This study investigates whether CGRP administration can trigger aura in individuals with a diagnosis of migraine with aura.",[64,63],[27,141,142],"Aura","Calcitonin gene-related peptide","RECRUITING","2025-08-03",{"date":146,"type":42},"2025-08-06",{"date":148,"type":42},"2025-06-27",{"date":75,"type":21},{"name":48,"class":49},{"id":152,"slug":153,"hasResults":11,"nctId":154,"briefTitle":155,"officialTitle":156,"acronym":4,"eligibilityCriteria":157,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":158,"targetDuration":4,"studyType":22,"phases":159,"briefSummary":160,"conditions":161,"keywords":163,"overallStatus":143,"whyStopped":4,"lastUpdateSubmitDate":167,"lastUpdatePostDateStruct":168,"startDateStruct":170,"completionDateStruct":172,"leadSponsor":174,"locationsCount":50},"100597519","hypersensitivity-to-adrenomedullin-in-post-traumatic-headache-100597519","NCT07059546","Hypersensitivity to Adrenomedullin in Post-Traumatic Headache","Hypersensitivity to Adrenomedullin in Post- Traumatic Headache: A Randomized Clinical Trial","Inclusion Criteria:\n\n* Age 18 to 65 years of age upon entry into screening\n* History of persistent headache attributed to mild traumatic injury to the head for ≥ 12 months and in accordance with the International Classification of Headache Disorders, 3rd Edition (ICHD-3)\n* ≥ 4 monthly headache days on average across the 3 months prior to screening\n* Provision of informed consent prior to initiation of any study-specific activities\u002Fprocedures.\n\nExclusion Criteria:\n\n* \\> 1 mild traumatic injury to the head\n* History of any primary or secondary headache disorder prior to mild traumatic injury to the head (except for infrequent episodic tension-type headache)\n* History of moderate or severe injury to the head\n* History of whiplash injury\n* History of craniotomy\n* History or evidence of any other clinically significant disorder, condition or disease (except for those outlined above) than, in the opinion of the site investigator, would pose a risk to subject safety or interfere with study evaluation, procedures or completion\n* The subject is at risk of self-harm or harm to others as evidenced by past suicidal behavior\n* Female subjects of childbearing potential with a positive pregnancy test during any study visit\n* Cardiovascular disease of any kind, including cerebrovascular diseases\n* Hypertension (systolic blood pressure of ≥150 mmHg and\u002For diastolic blood pressure of ≥100 mmHg) prior to the start of infusion on the experimental day\n* Hypotension (systolic blood pressure of ≤90 mmHg and\u002For diastolic blood pressure of ≤50 mmHg)\n* Initiation, discontinuation, or change of dosing of prophylactic medications within 2 months prior to study inclusion\n* Intake of acute medications (e.g. analgesics, triptans) within 48 hours of infusion start\n* Baseline headache intensity of \\>3 on an 11-point numeric rating scale (0 being no headache, 10 being the worst imaginable headache)\n* Baseline headache with migraine-like features or self-reported baseline headache that mimics the subjects' usual headache with migraine-like features",{"count":59,"type":21},[24],"Adrenomedullin is a neuropeptide implicated in the pathogenesis of headache. This study investigates whether adrenomedullin induces headache with migraine-like features in people with persistent post-traumatic headache (PTH) attributed to mild traumatic brain injury (mTBI).",[162],"Posttraumatic Headache",[164,165,166],"pain","adrenomedullin","posttraumatic headache","2025-07-28",{"date":169,"type":42},"2025-07-30",{"date":171,"type":21},"2025-08-01",{"date":173,"type":21},"2028-12-01",{"name":48,"class":49},{"id":176,"slug":177,"hasResults":11,"nctId":178,"briefTitle":179,"officialTitle":180,"acronym":4,"eligibilityCriteria":181,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":182,"targetDuration":4,"studyType":22,"phases":183,"briefSummary":184,"conditions":185,"keywords":186,"overallStatus":143,"whyStopped":4,"lastUpdateSubmitDate":188,"lastUpdatePostDateStruct":189,"startDateStruct":191,"completionDateStruct":193,"leadSponsor":195,"locationsCount":50},"100589791","substance-p-induced-migraine-attacks-without-aura-100589791","NCT06959004","Substance P-Induced Migraine Attacks Without Aura","Substance P-Induced Migraine Attacks Without Aura: A Randomized Clinical Trial","Inclusion Criteria:\n\n* Age 18 to 65 years of age upon entry into screening\n* A body weight of 50 to 100 kg\n* History of migraine without aura for ≥12 months and in accordance with ICHD-3\n* Between 1-5 monthly migraine days without aura on average across the 3 months prior to screening\n\nExclusion Criteria:\n\n* Any history of a primary or secondary headache disorder other than migraine without aura and infrequent episodic tension-type headache\n* Any history of moderate to severe traumatic brain injury\n* Any history of cardiovascular disease, including cerebrovascular diseases\n* Any history of pulmonary disease\n* Any other clinically significant disorders, conditions, or diseases that might impact the safety of the subject or interfere with the study's evaluation, procedures, or completion, aside from those mentioned above. This includes any relevant medical history or evidence that, in the opinion of the site investigator, might pose a risk to the subject or impact the validity of the study results\n* The subject is at risk of self-harm or harm to others as evidenced by past suicidal behavior\n* Female subjects of childbearing potential with a positive pregnancy test during any study visit\n* Cardiovascular disease of any kind, including cerebrovascular diseases\n* Hypertension (systolic blood pressure of ≥150 mmHg and\u002For diastolic blood pressure of ≥100 mmHg) prior to the start of infusion on the experimental day\n* Hypotension (systolic blood pressure of ≤90 mmHg and\u002For diastolic blood pressure of ≤50 mmHg)\n* Daily use of any medication other than contraceptives\n* Intake of any medication other than contraceptives within 48 hours of infusion start\n* Headache of any intensity within 48 hours of infusion start\n* Migraine attack within 5 days of infusion start\n* Aura within 48 hours of infusion start",{"count":59,"type":21},[24],"Substance P is a neuropeptide implicated in the pathogenesis of headache. This study investigates whether its administration can trigger migraine attacks in individuals with migraine without aura.",[27],[122,27,31,187],"Substance P","2025-06-01",{"date":190,"type":42},"2025-06-05",{"date":192,"type":42},"2025-05-13",{"date":194,"type":21},"2026-12-01",{"name":48,"class":49},{"id":197,"slug":198,"hasResults":11,"nctId":199,"briefTitle":200,"officialTitle":201,"acronym":4,"eligibilityCriteria":202,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":203,"enrollmentInfo":204,"targetDuration":4,"studyType":22,"phases":206,"briefSummary":208,"conditions":209,"keywords":4,"overallStatus":143,"whyStopped":4,"lastUpdateSubmitDate":210,"lastUpdatePostDateStruct":211,"startDateStruct":213,"completionDateStruct":215,"leadSponsor":217,"locationsCount":50},"100580578","phase-3-safety-and-efficacy-of-botulinum-toxin-a-in-patients-with-posttraumatic-headache-100580578","NCT06839118","Safety and Efficacy of Botulinum Toxin A in Patients With Posttraumatic Headache","Safety and Efficacy of Botulinum Toxin A in Patients With Posttraumatic Headache: a Double-blind, Randomized, Placebo-controlled, Parallel-group Trial and Investigation of Neuroinflammatory Biomarkers as Predictors of Efficacy","Inclusion Criteria:\n\n1. A diagnosis of persistent PTH according to criteria 5.2.2 Persistent headache attributed to mild traumatic injury to the head according to The International Classification of Headache Disorders 3rd edition.\n2. Age between 18 and 80 years.\n3. Subjects must have headache at least 15 days per month during the last 4 weeks to enter the baseline phase.\n4. During baseline phase subjects must experience moderate-to-severe headache at least 8 days and headache at least 15 days to enter the treatment phase (to be randomized).\n5. Fluency in Danish\n\nExclusion Criteria:\n\n1. More than 2 TBI's.\n2. Severe cardiovascular and cerebrovascular disease such as ischemic heart disease, myocardial infarction or previous stroke or transient ischemic attack, major CVD interventions during the last three months.\n3. Expected poor compliance, i.e., considered unlikely to be able to complete all protocol required study visits or procedures, and\u002For to comply with all required study procedures to the best of the subject's and investigator's knowledge.\n4. Ongoing and unstable severe psychiatric disease.\n5. Anamnestic or clinical symptoms of any kind that are deemed relevant for study participation by the physician who examines the patient.\n6. A history of migraine or tension-type headache more than 5 days per month before the TBI.\n7. Medication-overuse headache according to the according to The International Classification of Headache Disorders 3rd edition.\n8. A history of moderate-to-severe TBI, whiplash injury, or craniotomy.\n9. Change of preventive PTH treatment or treatment dose within two months prior to the baseline visit (see Section 6.4 for a full list of these medications).\n10. Previous treatment with injections of BTX-A in the head or face.\n11. Female subjects either pregnant, breastfeeding or with planned conception within the study period.\n12. Female subject of childbearing potential who is unwilling to use an acceptable method of effective contraception during the study. Acceptable methods of effective birth control include not having intercourse (true abstinence, when this is in line with the preferred and usual lifestyle of the subject), hormonal birth control methods (pills, shots\u002Finjections, implants, or patches), intrauterine devices, surgical contraceptive methods (vasectomy with medical assessment of the surgical success of this procedure or bilateral tubal ligation). Female subjects not of childbearing potential are defined as any female who: is post-menopausal by history, defined as:\n\n    1. Age ≥ 55 years with cessation of menses for 12 or more months, OR\n    2. Age \\\u003C 55 years but no spontaneous menses for at least 2 years, OR\n    3. Age \\\u003C 55 years and spontaneous menses within the past 1 year, but currently amenorrheic (e.g., spontaneous, or secondary to hysterectomy), AND with postmenopausal gonadotropin levels (luteinizing hormone and follicle-stimulating hormone levels \\> 40 IU\u002FL) or postmenopausal estradiol levels (\\\u003C 5 ng\u002FdL) or according to the definition of \"postmenopausal range\" for the laboratory involved OR underwent bilateral oophorectomy OR underwent hysterectomy OR underwent bilateral salpingectomy.\n13. Known allergy to any component of BTX-A.\n14. Infection at the proposed injection site.\n15. Known severe neuromuscular disorders or any degree of disorder affecting the neuromuscular transmission.\n16. Known comprised respiratory function.\n17. Member of investigational site staff or relative of the investigator.","80 Years",{"count":205,"type":21},80,[207],"PHASE3","The study is an investigator-initiated randomized, placebo-controlled, double-blind, parallelgroup trial. Eighty subjects with PTH will be included and randomized 1:1 for treatment with BTX-A or placebo (isotonic saline). The study comprises a 4-week baseline phase before injection of either active drug or placebo followed by a 12-week evaluation period. Treatment will be double-blind, and subjects will only receive one treatment cycle. Endpoints will be assessed in the evaluation period (weeks 5 to 8) compared to baseline (weeks -4 to -1).",[162],"2025-02-16",{"date":212,"type":42},"2025-02-21",{"date":214,"type":42},"2025-01-10",{"date":216,"type":21},"2026-08-01",{"name":48,"class":49},{"id":219,"slug":220,"hasResults":11,"nctId":221,"briefTitle":222,"officialTitle":222,"acronym":4,"eligibilityCriteria":223,"healthyVolunteers":224,"sex":225,"minAge":17,"maxAge":226,"enrollmentInfo":227,"targetDuration":4,"studyType":229,"phases":4,"briefSummary":230,"conditions":231,"keywords":4,"overallStatus":143,"whyStopped":4,"lastUpdateSubmitDate":232,"lastUpdatePostDateStruct":233,"startDateStruct":235,"completionDateStruct":237,"leadSponsor":239,"locationsCount":50},"100552274","investigation-of-functional-brain-features-in-women-with-migraine-100552274","NCT06470958","Investigation of Functional Brain Features in Women with Migraine","Inclusion Criteria:\n\nFor women with migraine\n\n\\- Episodic menstrually-related migraine without aura \\> 12 months according to the International Classification of Headache Disorders 3rd Edition (ICHD-3) criteria\n\nFor women with migraine and healthy women\n\n* 18-40 years of age\n* Weight 50-100 kg\n* Regular menstruation\n\nExclusion Criteria:\n\nFor women with migraine\n\n* Other primary headache disorders than migraine, except infrequent episodic tension-type headache according to the ICHD-3 criteria\n* Secondary headache disorders\n* Headache on the first scan day or 48 hours before the first scan\n* Absence of the menstruation for the past 12 months\n* Daily intake of medication of any kind except oral contraceptives\n* Ingestion of any type of medication later than 4 times the plasma half-life of the substance in question (on the day of the scan), except for oral contraceptives\n* Intake of coffee, tea or alcohol 12 hours prior to scan days\n* Fertile women not using safe contraception. Fertile women are defined as women without hysterectomy and \\\u003C 2 years postmenopausal women. Safe contraception includes the intrauterine device, oral contraceptive pills, surgical sterilization of the woman, depot progestogen or condoms\n* Change of hormonal contraceptives for the past 3 months\n* Perimenstrual syndrome\n* Pregnant or breastfeeding women\n* Information or clinical signs of:\n\n  * Hypertension (systolic blood pressure \\> 150 mm Hg and\u002For diastolic blood pressure \\> 100 mm Hg)\n  * Low blood pressure (systolic blood pressure \\\u003C 100 mm Hg and\u002For diastolic blood pressure \\\u003C 50 mm Hg)\n* Cardiovascular diseases of any kind, including cerebrovascular disease\n* Diabetes\n* Unregulated mental illness or substance abuse\n* Illnesses of any kind deemed incompatible by the examining physician for participation in the study\n* Contraindications to MRI (including metal in the body or claustrophobia)\n* Do not want to be informed about unexpected pathological findings on the MRI\n\nFor healthy women\n\n* History of any primary headache except infrequent episodic tension-type headache according to the ICHD-3 criteria\n* First degree family history of primary headache disorders except infrequent episodic tension-type headache according to the ICHD-3 criteria (max five days\u002Fmonth)\n* Secondary headache disorders\n* Headache during the menstrual period from 2 days before to 2 days after the first menstrual bleeding day\n* Headache on the first scan day or 48 hours before the first scan\n* Absence of the menstruation for the past 12 months\n* Daily intake of medication of any kind except oral contraceptives\n* Ingestion of any type of medication later than 4 times the plasma half-life of the substance in question (on the day of the scan), except for oral contraceptives\n* Intake of coffee, tea or alcohol 12 hours prior to scan days\n* Fertile women not using safe contraception. Fertile women are defined as women without hysterectomy and \\\u003C 2 years postmenopausal women. Safe contraception includes the intrauterine device, oral contraceptive pills, surgical sterilization of the woman, depot progestogen or condoms\n* Change of hormonal contraceptives for the past 3 months\n* Pregnant or breastfeeding women\n* Perimenstrual syndrome\n* Information or clinical signs of:\n\n  * Hypertension (systolic blood pressure \\> 150 mm Hg and\u002For diastolic blood pressure \\> 100 mm Hg)\n  * Low blood pressure (systolic blood pressure \\\u003C100 mm Hg and\u002For diastolic blood pressure \\\u003C 50 mm Hg) Investigation of functional brain features in women with migraine\n* Cardiovascular diseases of any kind, including cerebrovascular disease.\n* Diabetes\n* Unregulated mental illness or substance abuse\n* Illnesses of any kind deemed incompatible by the examining physician for participation in the study\n* Contraindications to MRI (including metal in the body or claustrophobia)\n* Do not want to be informed about unexpected pathological findings on the MRI",true,"FEMALE","40 Years",{"count":228,"type":21},40,"OBSERVATIONAL","This study aims to investigate whether the functional alterations in the brain of individuals with migraine appear before the peripheral vascular changes. This will be investigated using functional and structural neuroimaging in individuals with spontaneous menstually-related migraine.",[27],"2024-10-31",{"date":234,"type":42},"2024-11-04",{"date":236,"type":42},"2024-04-10",{"date":238,"type":21},"2026-01-31",{"name":48,"class":49},{"id":241,"slug":242,"hasResults":11,"nctId":243,"briefTitle":244,"officialTitle":245,"acronym":4,"eligibilityCriteria":246,"healthyVolunteers":224,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":247,"targetDuration":4,"studyType":22,"phases":248,"briefSummary":249,"conditions":250,"keywords":252,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":253,"lastUpdatePostDateStruct":254,"startDateStruct":256,"completionDateStruct":258,"leadSponsor":260,"locationsCount":50},"100564661","effects-of-substance-p-on-headache-induction-in-healthy-individuals-100564661","NCT06632080","Effects of Substance P on Headache Induction in Healthy Individuals","Effects of Substance P on Headache Induction in Healthy Individuals: a Randomized Clinical Trial","Inclusion Criteria:\n\n* Age 18 to 65 years of age upon entry into screening\n* A body weight of 50 to 100 kg\n* Provision of informed consent prior to initiation of any study-specific activities\u002Fprocedures.\n\nExclusion Criteria:\n\n* Any history of a primary or secondary headache disorder, except for infrequent episodic tensiontype headache\n* Any first-degree relatives with a history of a primary headache disorder, except for infrequent episodic tension-type headache\n* Any history of moderate to severe traumatic brain injury\n* Any history of cardiovascular disease, including cerebrovascular diseases\n* Any history of pulmonary disease\n* Any other clinically significant disorders, conditions, or diseases that might impact the safety of the subject or interfere with the study's evaluation, procedures, or completion, aside from those mentioned above. This includes any relevant medical history or evidence that, in the opinion of the site investigator, might pose a risk to the subject or impact the validity of the study results\n* The subject is at risk of self-harm or harm to others as evidenced by past suicidal behavior\n* Female subjects of childbearing potential with a positive pregnancy test during any study visit\n* Cardiovascular disease of any kind, including cerebrovascular diseases\n* Hypertension (systolic blood pressure of ≥150 mmHg and\u002For diastolic blood pressure of ≥100 mmHg) prior to the start of infusion on the experimental day\n* Hypotension (systolic blood pressure of ≤90 mmHg and\u002For diastolic blood pressure of ≤50 mmHg)\n* Abnormalities on the electrocardiogram that, in the opinion of the site investigator, might pose a risk to the subject or impact the validity of the study results\n* Daily use of any medication other than contraceptives\n* Intake of any medication other than contraceptives within 48 hours of infusion start\n* Intake of caffeine, nicotine, and alcohol within 12 hours of infusion start\n* Headache of any intensity within 48 hours of infusion start",{"count":59,"type":21},[24],"Substance P is a signaling molecule that has been implicated in the pathogenesis of headache. This study aims to ascertain whether administration of substance P can induce headache in healthy adults.",[251],"Healthy Volunteers Only",[122],"2024-10-11",{"date":255,"type":42},"2024-10-15",{"date":257,"type":21},"2024-10-14",{"date":259,"type":21},"2025-12-31",{"name":48,"class":49},{"id":262,"slug":263,"hasResults":11,"nctId":264,"briefTitle":265,"officialTitle":265,"acronym":4,"eligibilityCriteria":266,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":267,"targetDuration":269,"studyType":229,"phases":4,"briefSummary":270,"conditions":271,"keywords":4,"overallStatus":143,"whyStopped":4,"lastUpdateSubmitDate":273,"lastUpdatePostDateStruct":274,"startDateStruct":276,"completionDateStruct":278,"leadSponsor":280,"locationsCount":281},"100364987","diagnostic-and-prognostic-biomarkers-of-idiopathic-intracranial-hypertension-100364987","NCT04032379","Diagnostic and Prognostic Biomarkers of Idiopathic Intracranial Hypertension","Inclusion Criteria:\n\n1. Able to and willing to provide informed consent\n2. More than 18 years of age\n3. Suspicion of IIH (based on clinical evaluation by neurologist or opthalmologist)\n\nExclusion Criteria:\n\n1.) Unable to consent (e.g. language, mental retardation).",{"count":268,"type":21},300,"5 Years","Idiopathic intracranial hypertension (IIH) is a condition of unknown etiology, primarily affecting overweight females of childbearing age. Typically, patients experience headache and visual symptoms due to increased intracranial pressure (ICP) and papilledema. The diagnosis is difficult, and outcomes vary from no sequelae to blindness or chronic headaches. No clear prognostic indicators exist. Treatment consists of medication, weight loss, and possibly surgical intervention.There is an unmet need of defining biomarkers with prognostic or diagnostic value and defining predictors of a poor outcome.\n\nThis project is a prospective, population-based cohort study including clinical data and a biobank (blood samples and cerebrospinal fluid).\n\nThe investigator's primary aim is to identify biomarkers of diagnostic or prognostic value and to create a clinical IIH database. The clinical database will answer questions about patient characteristics at baseline and during follow-up, identify predictors of outcome, and help create a standardized programme for follow-up and",[272],"Benign Intracranial Hypertension","2023-03-06",{"date":275,"type":42},"2023-03-07",{"date":277,"type":42},"2018-02-14",{"date":279,"type":21},"2027-05-31",{"name":48,"class":49},2,""]